Oculis’ (OCS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Oculis (NASDAQ:OCS) in a research note released on Monday,Benzinga reports. They currently have a $30.00 target price on the stock.

Oculis Trading Up 2.6 %

Shares of OCS stock opened at $18.70 on Monday. The company has a market capitalization of $757.42 million, a P/E ratio of -9.69 and a beta of -0.33. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $16.38 and its two-hundred day moving average is $13.87. Oculis has a twelve month low of $10.50 and a twelve month high of $18.72.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.